Summary
This multicentre randomised controlled trial (CheckMate 901) evaluated the addition of nivolumab, a PD-1 immune checkpoint inhibitor, to standard first-line chemotherapy (gemcitabine-cisplatin) in advanced urothelial carcinoma. The combination therapy demonstrated significantly improved clinical outcomes compared to chemotherapy alone, supporting a new treatment paradigm for this aggressive malignancy.
Regional applicability
These findings are directly applicable to UK clinical practice, as nivolumab is available through the NHS and this trial establishes an evidence base for its use in combination chemotherapy regimens for advanced urothelial carcinoma within the UK healthcare system.
Key measures
Overall survival, progression-free survival, objective response rate, adverse events
Outcomes reported
The study measured overall survival, progression-free survival, objective response rates, and safety outcomes in patients with previously untreated advanced urothelial carcinoma receiving combination nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.